NASDAQ:EDIT

Editas Medicine Stock Forecast, Price & News

$63.20
+2.20 (+3.61 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$59.23
$63.54
50-Day Range
$39.27
$72.94
52-Week Range
$27.01
$99.95
Volume2.16 million shs
Average Volume2.00 million shs
Market Capitalization$4.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.95
30 days | 90 days | 365 days | Advanced Chart
Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.


Editas Medicine logo

About Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Headlines

Fast Money Halftime Report Picks For September 13
'Fast Money Halftime Report' Picks For September 13
September 13, 2021 |  benzinga.com
Editas Medicine (NASDAQ:EDIT) Shares Gap Up to $64.45
Editas Medicine (NASDAQ:EDIT) Shares Gap Up to $64.45
September 10, 2021 |  americanbankingnews.com
Editas Medicine (NASDAQ:EDIT) Upgraded to Outperform by Oppenheimer
Editas Medicine (NASDAQ:EDIT) Upgraded to Outperform by Oppenheimer
September 9, 2021 |  americanbankingnews.com
Editas Medicine Names Emma Reeve to Board of Directors
Editas Medicine Names Emma Reeve to Board of Directors
September 8, 2021 |  finance.yahoo.com
Why You Need to Avoid These 3 Downgraded Stocks
Why You Need to Avoid These 3 Downgraded Stocks
September 7, 2021 |  stocknews.com
Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?
Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?
September 3, 2021 |  finance.yahoo.com
Is Editas Medicine (NASDAQ:EDIT) A Risky Investment?
Is Editas Medicine (NASDAQ:EDIT) A Risky Investment?
September 1, 2021 |  finance.yahoo.com
Editas Medicine (NASDAQ:EDIT) Trading Down 5.9%
Editas Medicine (NASDAQ:EDIT) Trading Down 5.9%
August 30, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

848th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

127th out of 193 stocks

Analyst Opinion: 2.1Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

Is Editas Medicine a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 sell ratings, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine
or view top-rated stocks.

What stocks does MarketBeat like better than Editas Medicine?

Wall Street analysts have given Editas Medicine a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Editas Medicine wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Editas Medicine
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm earned $0.38 million during the quarter, compared to analyst estimates of $6.78 million. Editas Medicine had a negative trailing twelve-month return on equity of 31.96% and a negative net margin of 205.41%. Editas Medicine's revenue for the quarter was down 96.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.43) earnings per share.
View Editas Medicine's earnings history
.

How has Editas Medicine's stock price been impacted by COVID-19?

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EDIT shares have increased by 211.8% and is now trading at $63.20.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EDIT?

15 brokers have issued twelve-month target prices for Editas Medicine's stock. Their forecasts range from $14.00 to $86.00. On average, they expect Editas Medicine's share price to reach $56.53 in the next twelve months. This suggests that the stock has a possible downside of 10.5%.
View analysts' price targets for Editas Medicine
or view top-rated stocks among Wall Street analysts.

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:
  • James C. Mullen, Chairman, President & Chief Executive Officer
  • Harry R. Gill, Senior Vice President-Operations
  • Michelle Robertson, Treasurer, Chief Financial & Accounting Officer
  • Lisa A. Michaels, Chief Medical Officer & Executive Vice President
  • Mark S. Shearman, Chief Scientific Officer & Executive VP

Who are some of Editas Medicine's key competitors?

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (10.59%), Vanguard Group Inc. (9.50%), BlackRock Inc. (8.23%), Sumitomo Mitsui Trust Holdings Inc. (7.19%), Nikko Asset Management Americas Inc. (7.18%) and State Street Corp (3.71%). Company insiders that own Editas Medicine stock include Charles Albright, Cynthia Collins and Michelle Robertson.
View institutional ownership trends for Editas Medicine
.

Which major investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Federated Hermes Inc., Renaissance Technologies LLC, Morgan Stanley, Morgan Stanley, BlackRock Inc., Segall Bryant & Hamill LLC, and Group One Trading L.P.. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, and Michelle Robertson.
View insider buying and selling activity for Editas Medicine
or view top insider-selling stocks.

Which major investors are buying Editas Medicine stock?

EDIT stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Dimensional Fund Advisors LP, Discovery Value Fund, State Street Corp, Parallax Volatility Advisers L.P., and JPMorgan Chase & Co..
View insider buying and selling activity for Editas Medicine
or or view top insider-buying stocks.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $63.20.

How much money does Editas Medicine make?

Editas Medicine has a market capitalization of $4.31 billion and generates $90.73 million in revenue each year. The company earns $-115,980,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis.

How many employees does Editas Medicine have?

Editas Medicine employs 235 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

Where are Editas Medicine's headquarters?

Editas Medicine is headquartered at 11 Hurley Street, Cambridge MA, 02141.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at (617) 401-9000 or via email at [email protected]


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.